Aligos Therapeutics
ALGS
48 hedge funds and large institutions have $16.6M invested in Aligos Therapeutics in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more funds holding
Funds holding: 48 → 48 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.03% less ownership
Funds ownership: 2.55% → 2.52% (-0.03%)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
63% less capital invested
Capital invested by funds: $45.3M → $16.6M (-$28.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.78M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$855K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$409K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$374K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$352K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$607K |
| 2 |
NM
Newtyn Management
New York
|
-$338K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$260K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$233K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$90.2K |
ALGS Hedge Fund Activity: Q2 2024 in Review
48 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q2 2024, worth a combined $16.6M — down 63% from $45.3M a quarter earlier.
Fund positioning in ALGS was balanced in Q2 2024: 8 funds opened new positions, 8 closed out, 11 added to existing stakes and 13 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $1.78M. The largest seller was Versant Venture Management, cutting an estimated $607K.
- 48 institutional investors held Aligos Therapeutics (ALGS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $16.6M of Aligos Therapeutics stock for Q2 2024, down 63% quarter-over-quarter.
- 8 funds opened new Aligos Therapeutics positions in Q2 2024 and 8 closed out, a net change of 0 holders.
- The largest Aligos Therapeutics buyer in Q2 2024 was Adage Capital Partners, an estimated $1.78M added.
- The largest Aligos Therapeutics seller in Q2 2024 was Versant Venture Management, an estimated $607K sold.
Based on aggregated 13F filings for Q2 2024.